Cabaletta Bio, Inc. Common Stock
Here’s whether Cabaletta Bio, Inc. Common Stock (CABA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.18% over 10 days); RSI 48 — healthy momentum range; strong 1-year return of +49.1%. Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.75x 30d avg). Currently 23.2% off its 52-week high. Score: +3/7.
CABA is holding above its long-term 200-day MA ($2.69) but has slipped below the 50-day MA ($3.33), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +49.1% compares to +24.4% for SPY (beat the market by 24.7%). The current 23.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.